Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia

Leukemia

Volumn 12, Issue 11, 1998, Pages 1699-1707

  Sutton, L ^a   Maloum, K ^a   Gonzalez, H ^a   Zouabi, H ^a   Azar, N ^a   Boccaccio, C ^a   Charlotte, F ^a   Cosset, J M ^b   Gabarre, J ^a   Leblond, V ^a   Merle Beral, H ^a   Binet, J L ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT CURIE   (France)

Author keywords

Advanced disease; Autologous transplantation; B CLL; Hematopoietic stem cell

Indexed keywords

AMINOGUANIDINE; CHLORAMBUCIL; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; B CELL LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; PRIORITY JOURNAL; SALVAGE THERAPY;

EID: 17344372971     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401201     Document Type: Article

References (33)

1. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, Van Besien KW, Mehra RC, Giralt SA, Ippoliti C, Marshall M, Thomas MW, O'Brien S, Robertson LE, Deisseroth AB, Champlin RE. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748-758.
2. Rabinowe SN, Soiffer RJ, Gribben JG, Daley H, Freedman AS, Daley J, Pesek K, Neuberg D, Pinkus G, Leavitt PR, Spector NA, Grossbard ML, Anderson K, Robertson MJ, Mauch P, Chayt-Marcus K, Ritz J, Nadler LM. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B cell chronic lymphocytic leukemia. Blood 1993; 82: 1366-1376.
3. Provan D, Bartlett-Pandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P, Soiffer R, Ritz J, Nadler LM, Gribben JG. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996; 88: 2228-2235.
4. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878-2884.
5. Catovsky D, Fooks J, Richards S for the MRC Working Party on Leukaemia in Adults. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. Br J Haematol 1989; 72: 141-149.
6. Keating MJ, O'Brien S, Robertson L, Huh Y, Kantarjian H, Plunkett W. Chronic lymphocytic leukemia - correlation of response and survival. Leuk Lymphoma 1993, 2: 167-175.
7. Leporrier M, Chevret S, Cazin B, Feugier P, Rapp MJ, Boudjerra N, Autrand C, Dreyfus B, Desablens B, Dighiero C, Travade P, Chastang C, Binet JL. Randomised comparison of fludarabin, CAP and ChOP, in 695 previously untreated stage B and C chronic lymphocytic leukemia. Early stopping of the CAP accrual. Blood 1997; 90: 529a, Abstr. 2357.
8. Keating MJ, Lerner S, O'Brien S. Long-term results with fludarabine in CLL. VII International Workshop on CLL. Crete, Greece, 1997, p 13, Abstr. 13.
9. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubinstein E, Cabanillas F. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169-1176.
10. Philips GL, Herzig TH, Lasarus HM, Fay W, Wolf SN, Mill WB, Lin HN, Thomas PR, Glasgow GP, Shina DC, Herzig GP. Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation and transplantation of cryopreserved autologous marrow. New Engl J Med 1984; 310: 1557-1561.
11. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M, Laporte JP, Maraninchi D, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New Engl J Med 1987; 316: 1493-1498.
12. Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, Spitzer G, Velasquez W, Weisenburger DD, Fernandez-Ranada J, Somers R, Rizzoli V, Harousseau JL, Sotto JJ, Cahn JY, Guilhot F, Biggs J, Sonneveld P, Misset JL, Manna A, Jagannath S, Guglielmi G, Chevreau C, Delmer A, Santini G, Coiffier B. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991; 77: 1587-1592.
13. Foon KA, Rai KR, Gale RP. Chronic lymphocytic leukemia: new insights into biology and therapy. Ann Intern Med 1990; 113: 525-539.
14. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, Foon KA. Guidelines for clinical protocols for chronic lymphocytic leukemia: report of the NCI-sponsored Working Group. Am J Hematol 1988; 29: 152-163.
15. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B cell lymphoma. New Engl J Med 1991; 325: 1525-1533.
16. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-2258.
17. Cheson BD, Bennet JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group Guidelines for Chronic Lymphocytic Leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
18. Robertson LE, Huh YO, Butler JJ, Pugh WC, Hirsch-Ginsberg C, Stass S, Kantarjian H, Keating MJ. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic and molecular analysis. Blood 1992; 80: 29-36.
19. Rozman C, Montserrat E, Rodriguez-Fernandez JM, Ayats R, Vallespi T, Parody R, Rios A, Prados D, Morey M, Gomis F, Alcala A, Gutierrez M, Maldonado J, Gonzalez C, Giralt M, Hernandez-Nieto L, Cabrera A, Fernandez-Ranada JM. Bone marrow histologic pattern - the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64: 642-648.
20. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the classification of chronic (mature) B and T lymphoid leukemias. J Clin Pathol 1989; 42: 567-584.
21. Nadler LM. B cell leukemia panel workshop: summary and comments. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID (eds). Leukocyte Typing II. Springer-Verlag: New York, NY, 1986, pp 3-43.
22. Vuillier F, Claisse JF, Vandenvelde C, Travade P, Magnac C, Chevret S, Desablens B, Binet JL, Dighiero G. Evaluation of residual disease in B cell chronic lymphocytic leukemia patients in clinical and bone marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk Lymphoma 1992; 7: 195-204.
23. Maloum K, Pritsch O, Dighiero G. Minimal residual disease detection in B cell malignancies by assessing IgH rearrangement. Hematol Cell Ther 1997; 39: 1-6.
24. Maloum K, Magnac C, Sutton L, Leblond V, Cazin B, Boccaccio C, Davi F, Binet JL, Merle-Béral H, Dighiero C. Minimal residual disease assessment in chronic lymphocytic leukemia. Blood 1996; 88: 77a, Abstr. 297.
25. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
26. Leporrier M, Reman O, Troussard X, Levaltier X, Vie B. Double hemibody irradiation with GM-CSF as salvage therapy for refractory chronic lymphocytic leukemia. Leuk Lymphoma 1994; 16: 121-124.
27. O'Brien S, Kantarjian H, Beran M, Freireich E, Kornblau S, Koller C, Lerner S, Gilbreath J, Keating M. Fludarabine and cyclophosphamide therapy in chronic lymphocytic leukemia. Blood 1996; 88: 480a, Abstr. 1910.
28. Rozman C, Montserrat E. Chronic lymphocytic leukemia. New Engl J Med 1995; 333: 1052-1057.
29. Montserrat E, Gomis F, Vallespi T, Rios A, Romero A, Soler J, Alcala A, Morey M, Ferran C, Diaz-Mediavilla J, Flores A, Woessner S, Batlle J, Gonzalez-Aza C, Monserrat R, Reverter JC, Rozman C. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood 1991; 78: 1545-1551.
30. Österborg A, Fassas AS, Anagnostopoulos A, Dyer MJS, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996; 93: 151-153.
31. Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJS, Catovsky D. Subcutaneous Campath-1H in fludarabine-resistant/relapsed chronic lymphocytic leukaemia and B-prolymphocytic leukemia. Br J Haematol 1997; 96: 617-619.
32. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
33. Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton G, Montserrat E, Rozman C, Gratwohl A, Gale RP. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 1996; 124: 311-315.